Form D On Watch: Inform Genomics $1.45 million Financing. Edward B Rubenstein Released Oct 28 Form D

Biotechnology Inform Genomics, Inc. - Edward B Rubenstein

Inform Genomics Financing

Inform Genomics, Inc., Corporation just released form D regarding $1.45 million equity financing. This is a new filing. Inform Genomics, Inc. is expected to finance itself with $1.45 million in this fundraising offer. The total fundraising amount was $1.45 million. The fundraising form was filed on 2016-10-28. The reason for the financing was: The Issuer has an employment agreement with the CEO/President, Edward Rubenstein, under which he is paid $260,000 on an annual basis.. The fundraising still has about $1.45 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Inform Genomics is based in Massachusetts. The firm’s business is Biotechnology. The form was filed by Edward B Rubenstein President & CEO. The company was incorporated more than five years ago. The filler’s address is: 101 Federal Street, Suite 1900, Boston, Ma, Massachusetts, 02110. Edward B Rubenstein is the related person in the form and it has address: 101 Federal Street, Suite 1900, Boston, Ma, Massachusetts, 02110. Link to Inform Genomics Filing: 000153798816000006.

Analysis of Inform Genomics Offering

On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Inform Genomics sold 0.00% of the offering. The fundraising is still open. The average fundraising amount for companies in the Biotechnology industry is $3.08 million. The offering was 100.00% smaller than the average of $3.08 million. Of course this should not be interpreted as negative. Companies raise funds for a variety of reasons and needs. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Inform Genomics Also

The Form D signed by Edward B Rubenstein might help Inform Genomics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment